You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202171 - 202180 of 207728 results
  1. Fibrosis-Resistant Bleb-Free Gaucoma Implant

    SBC: HEALIONICS CORPORATION            Topic: NEI

    DESCRIPTION (provided by applicant): The objective of this Phase I SBIR project is to test the feasibility of using a novel biomaterial design for improved Glaucoma Drainage Device (GDD) performance. The proposed innovation has the eventual aim to enhanceour current STARfloTM Glaucoma Implant device by increasing its drainage efficiency with a fibrosis-minimizing surface geometry. This could allow ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Adaptive Optics OCT/Fluorescence Small Animal Imager

    SBC: PHYSICAL SCIENCES INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Physical Sciences Inc. proposes to develop a new, integrated multimodal adaptive optics small animal imager, including AO-OCT and AO scanning laser fluorescence (fAOSLO), and to demonstrate its applications to detectingpathology in the retinas of rodent models of eye disease. The imaging platform includes novel design elements such as adaptable wavefront sensin ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A Rapid, Portable Test to Monitor Gradual Vision Loss in Dry Age-Related Macular

    SBC: ADAPTIVE SENSORY TECHNOLOGY, LLC            Topic: NEI

    DESCRIPTION (provided by applicant): The worldwide demographic trends of aging and obesity will increase the global incidence of blinding eye diseases, which impose significant psychosocial and economic burdens. The leading cause of blindness in the developed world is Age-related Macular Degeneration (AMD), which causes the progressive loss of central vision. Because dry AMD, which exhibits gradua ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Investigation of PEGylated BA-210 for RGC neuroprotection

    SBC: BIOAXONE BIOSCIENCES, INC.            Topic: NEI

    Project summary Inhibitors of Rho GTPase are neuroprotective for retinal ganglion cell (RGCs) and may be effective in treating eye diseases such as glaucoma. RGC death in glaucoma is associated with RGC axonal loss. Once neurons lose connections, normal circuitry is affected, and the loss of target-derived signals contributes to cell death. Such loss of signals may be dendritic or axonal, and prev ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Comprehensive Assessment of Retinal Vasculature (CARV)

    SBC: VisionQuest Biomedical Inc            Topic: NEI

    Summary Teleretinal programs have expanded in recent years, primarily to screen for diabetic retinopathy. Accurate and consistent assessment of the retinal vasculature, which often sustains damage as a result of cardiovascular disease, would advance teleretinal screening in terms of robustness and cost. Unfortunately, assessing changes to the retinal vasculature and quantifying abnormalities in re ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. CLFB143 Analogs to Treat Glaucoma

    SBC: CALIFIA BIO, INC.            Topic: NEI

    Project Summary Glaucoma is the leading cause of irreversible blindness worldwide. In glaucoma, retinal ganglion cells (RGCs), the projection neurons that transmit vision from the retina to the brain, are injured and die, partially as a result of increasedintraocular pressure (IOP). Current therapies (laser, surgery and eye drops) all act by lowering IOP. Unfortunately, lowering IOP can produce un ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Selective induction of endogenous IL10 for the treatment of uveitis

    SBC: ANVIL BIOSCIENCES LLC            Topic: NEI

    Project Summary Uveitis is an inflammatory disease of the eye that if inadequately treated can lead to vision impairment and blindness. Since the 1950's corticosteroids have been used as the main treatment option despite side effects from prolonged usagein severe and chronic uveitis. Research into uveitis has uncovered its underlying autoimmune mechanisms as facilitated by pathogenic lymphoc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Peripheral administration of nonpeptide somatostatin agonists for ophthalmic dise

    SBC: Crinetics Pharmaceuticals, Inc.            Topic: NEI

    Project Summary With an increasing older population, including the generational aging of the baby boomers , age-related eye diseases are common and becoming more prevalent. Currently, it is estimated that 11 million Americans suffer from age-related macular degeneration (AMD) - a number that is expected to double in the next generation. The first world diabetes epidemic has also brought about a s ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Confocal and Autofluorescence Imaging of Macular Degeneration using a Low Cost Di

    SBC: AEON IMAGING LLC            Topic: NEI

    Project Summary / Abstract - PA-13-088 The overall goal of the proposed SBIR Phase I research is to build and begin initial evaluation of a low cost, portable retinal camera used to detect age-related macular degeneration and other retinal degenerations.Age-related macular degeneration remains the most common cause of permanent vision loss in the US and industrialized countries. The specialized i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A Wnt Modulator for Treatment of Age-related Macular Degeneration

    SBC: Charlesson, LLC            Topic: NEI

    PROJECT SUMMARY/ABSTRACT Age-related macular degeneration (AMD) is characterized by progressively decreased central vision and visual acuity and remains a leading cause of vision loss and blindness in aged Americans. Currently, the standard of care for AMD is intravitreal vascular endothelial growth factor (VEGF) inhibitors. Clinical studies have demonstrated that anti-VEGF drugs can slow or reve ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government